MICROPORT (00853) surged more than 4%, and as of the time of writing, the stock was up 4.34% to HK$12.27, with a turnover of HK$79.5315 million. On the news front, MICROPORT previously announced that the independent shareholders of MicroPort CardioFlow Medtech Corporation had approved the merger agreement and the proposed transactions thereunder at an extraordinary general meeting held on December 15, 2025. The merger is expected to be completed on or around December 19, 2025. The announcement stated that this strategic merger is a key initiative for the company to optimize resource allocation and enhance overall competitiveness, aiming to comprehensively strengthen synergies between the two parties in the fields of structural heart disease and rhythm management. Citi pointed out that MICROPORT's fundamentals continue to improve, with the company's net loss narrowing by 66% year-on-year in the first half of 2025. The bank expects the company to record a profit in the second half of 2025. Additionally, the bank anticipates that the high-growth overseas platform will achieve a 70% to 80% year-on-year increase in 2025, and this growth trend may continue into 2026. The company is also expected to benefit from synergies following the merger, which will become an upside potential for the firm. Everbright Securities believes that, considering factors such as the impact of centralized procurement, the company's efforts to reduce various expenses, and its focus on core businesses, MICROPORT is expected to achieve continued loss reduction. The securities firm has raised its net profit forecasts for 2025-2026 to -US$30 million / US$96 million (previously -US$59 million / US$91 million).